30 results about "Mucosal healing" patented technology

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and / or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and / or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

A system and method are disclosed, which combine image data of a patient, such as images of the patient's GI tract, with rating mucosal damage. According to some embodiments of the present invention the system and method are able to assess a patient's GI tract condition, to monitor mucosal healing in a patient's GI tract, preferably, the small bowel (SB) mucosa and / or to differentiate between different pathological conditions. The system and method of the invention can provide a value or score arrived at by assigning a grade relating to one or more predetermined parameters.

A system and method are disclosed, which combine image data of a patient, such as images of the patient's GI tract, with rating mucosal damage. According to some embodiments of the present invention the system and method are able to assess a patient's GI tract condition, to monitor mucosal healing in a patient's GI tract, preferably, the small bowel (SB) mucosa and / or to differentiate between different pathological conditions. The system and method of the invention can provide a value or score arrived at by assigning a grade relating to one or more predetermined parameters.

The invention comprises 1) an oral composition, including an oral rehydration composition or solution, comprising an effective amount of a compound selected from epidermal growth factor (EGF) and agonists to the epidermal growth factor receptor, 2) a kit comprising an oral rehydration composition containing an effective amount of a compound selected from epidermal growth factor and agonists to the epidermal growth factor receptor, and 3) methods for the treatment and prevention of dehydration and diarrhea, and enhancing intestinal healing, reducing bacterial colonization, reducing the incidence of weight loss, increasing food uptake, enhancing rehydration, and enhancing mucosal healing in an animal having diarrhea.

The present invention provides methods for personalized therapeutic management of a disease in order to optimize therapy and / or monitor therapeutic efficacy. In particular, the present invention comprises measuring an array of one or a plurality of biomarkers at a plurality of time points over the course of therapy with a therapeutic agent to determine a mucosal healing index for selecting therapy, optimizing therapy, reducing toxicity, and / or monitoring the efficacy of therapeutic treatment. In certain instances, the therapeutic agent is a TNFα inhibitor for the treatment of a TNFα-mediated disease or disorder.

The application relates to synthetic composition containing one or more human milk mono- or oligosaccharides which promote mucosal healing in inflammatory GI conditions of humans.

Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.

The invention relates to a sustained release medicine bracket for a nasal cavity. The sustained release medicine bracket for the nasal cavity comprises a main body and at least one bottom, wherein the main body is of a grid structure formed by interweaving silk yarns or tows with each other. The main body extends circumferentially and has tail ends relative to each other; the bottom protrudes outwardly in a curved-surface shape; the periphery of the bottom is aligned and connected with the edges of the tail ends; the main body and the bottom carry a medicine which can be sustainedly released for the treatment of nasosinusitis. The invention further discloses a method for forming the sustained release medicine bracket for the nasal cavity. According to the sustained release medicine bracket for the nasal cavity, the wall surface of the main body is used for the wall-attaching treatment of a wound surface, at the same time, the bottom is used to stretch into a concave pit of the disease sites for the wall-attaching treatment, so as to act on the inflammation in the concave pit, accordingly, mucosal inflammatory and edema are effectively relieved, mucosal healing is promoted, scar formation is reduced, and postoperative adhesions are eliminated.

of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

The invention provides a medicine for coordinating intestines and the stomach. The medicine comprises the following raw materials in parts by weight: 12-18 parts of white hyacinth beans, 12-18 parts of Chinese yam, 7-13 parts of codonopsis pilosula, 5-13 parts of pericarpium citri reticulatae, 1-5 parts of mangnolia officinalis, 1-5 parts of fructus amomi, 7-13 parts of rhizoma atractylodis macrocephalae, 9-15 parts of poria cocos, 1-5 parts of radix aucklandiae and 2-22 parts of stachyose. The medicine has the beneficial effects that effective components of the medicine are quickly absorbed, and the medicine has the effects of invigorating spleen and replenishing qi, harmonizing stomach and descending turbidity, promoting qi circulation and removing stagnation, protecting gastric mucosa and promoting healing of damaged gastric mucosa, can regulate intestinal flora, proliferate beneficial bacteria, inhibit harmful bacteria and improve gastrointestinal functions, is quick in effect, good in curative effect, stable in effect, wide in application range, completely free of toxic and side effects, good in taste, and slightly bitter and sweet, is easily accepted by most patients, and has mild properties and long shelf life.

The present disclosure provides methods for assessing mucosal healing in a patient with Chron's Disease. The methods include detecting expression levels of analytes in a serum sample from a patient, and applying a mathematical algorithm to the expression levels, thereby producing a Mucosal Healing Index score for the patient. The present disclosure also provides kits that include two or more binding partners, each or which is capable of binding a different analyte measured in the disclosed mucosal healing assessment methods.

The invention discloses a degradable 3D printing nasal sinus stent loaded with drugs and a preparation method thereof. The stent can be implanted after sinus dilation to prevent nasal adhesion, and the stent can be slowly degraded along with the release of drugs, which can affect the lesion location. Continue treatment with medication. The invention uses degradable PLA material as raw material, adopts 3D printing technology, and fuses the drug load into the process of forming the 3D printing material. The drug release cycle of the stent is consistent with the material degradation cycle, which can meet the time requirement for wound healing after sinus dilation surgery, and can effectively solve the problem of short drug release time for general drug-coated stents. The degradable drug support for the nasal cavity and paranasal sinuses obtained by the invention can reduce mucosal inflammation and edema, promote mucosal healing, reduce scar formation, and eliminate postoperative adhesions, thereby alleviating the pain of patients and reducing the economic burden of patients.

The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented.

The invention belongs to the field of life health care, and relates to a bio-enzyme anti-inflammatory and bacteriostatic repair gel. The bio-enzyme anti-inflammatory and bacteriostatic repair gel comprises the following components in percentage by mass: 0.7-1.4% of a thickening agent, 0.6-1% of allantoin, 0.5-1% of compound biological enzyme, 1-3% of butanediol, 0.1-0.5% of a radix sophorae flavescentis extract, 0.5-3% of an aloe extract and the balance of water. The gel can effectively clear free radicals, resist oxidation, delay senescence, nourish, tender and white, sterilize and diminish inflammation, inhibit bacteria and diminish swelling, clean and expel toxins, expel parasites and relieve itching, repair mucous membranes, heal injury, nurse uterus, maintain ovary, regulate menstruation and relieve pain, moisturize and moisten, shrink and tighten vagina, prevent dryness, target conditioning and prevent various gynecological diseases, improve private environment, repair the mucous membrane barrier function, activate cells, and simulate the young state of the uterus environment.

From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.

Methods and compositions are provided that use proline, serine and threonine to promote healing of the intestinal mucosa. A therapeutically effective amount of proline, serine and threonine is administered to an individual in need thereof, for example a human or other mammal, such as an individual that has damaged intestinal mucosa. The methods and compositions can promote mucosal healing, restore gut barrier function, repair intestinal epithelial cells, promote protection of the colonic epithelium, and / or promote the replenishment of goblet cells in the intestinal and colonic mucosa.

The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state, and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered. Establishing the baseline may include enterally administering a first dosage of a composition comprising a fluorescent tracer, measuring a first amount of the administered dose that can be found outside the gut over a period of time, and determining a baseline total percentage of the administered dose recovered. Measuring gut permeability may include enterally administering a second dosage of the composition, measuring a second amount of the administered dose, and determining a second total percentage of the administered dose recovered.

The present invention provides methods for predicting the likelihood of mucosal healing in an individual with inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC). In addition, the present invention provides methods for monitoring the progression of mucosal healing in an individual with a disease such as IBD. Information on mucosal healing status derived from the use of the present invention can also aid in optimizing therapy and / or monitoring the therapeutic efficiency of an anti-TNFα inhibitor drug.

Oral cavity wound healing occurs in an environment that sustains ongoing physical trauma and is rich in bacteria. Patients undergoing cleft palate repair have a high degree of wound healing complications, such as oronasal fistula (ONF) formation. Following hard palate injury, ONF was created that demonstrated little change in pro-regenerative monocytes LY6Clo monocytes; however, there were increased M2 macrophages observed. Delivery of FTY720 nanofiber scaffolds following hard palate injury prevented ONF formation, allowed complete wound healing and was associated with increased LY6Clo monocytes and pro-regenerative M2 macrophages. Evaluation of interleukin gene expression revealed reduction in pro-inflammatory IL1 and IL6 and increased expression of pro-regenerative IL10 with FTY720 nanofiber delivery. The ability of FTY720 scaffolds to increase LY6Clo monocytes, increase M2 macrophages and alter the interleukin expression during hard palate mucosal healing demonstrates the ability of a FTY720-based autotherapy to improve oral cavity wound healing.

From experiments using colitis model mice, the present inventors discovered that siRNAs that suppress the CHST15 gene expression have a therapeutic effect against Crohn's disease or ulcerative colitis. Specifically, the present inventors discovered that the siRNAs which suppress the CHST15 gene expression can serve as an agent for promoting mucosal healing, in particular, an agent for treating Crohn's disease or ulcerative colitis, and thereby completed the present invention.

The present invention provides methods for measuring the total and / or activation levels of one or more analytes such as HER1, HER2, HER3, cMET, IGF-1R, PI3K, AKT, PRAS40, MEK, RSK, JAK1, STAT1, STAT3, TNFα, and / or anti-TNFα drug to determine whether a subject with inflammatory bowel disease (IBD) has non-inflamed and / or non-involved or inflamed and / or involved gastrointestinal tissue. The methods of the present invention can be used to evaluate mucosal healing, to diagnose, prognose, and monitor the progression of IBD, and to select and monitor the therapeutic response to IBD therapy.

Methods and compositions for treating inflammatory bowel disease by promoting mucosal healing in the gastrointestinal (GI) tract are encompassed herein. More particularly, methods and compositions described herein relate to agents that activate mononuclear phagocytes (MNPs) in the GI tract and, in turn, regulate the activity of interleukin (IL)-22-producing group 3 innate lymphoid cells (ILC3) in close proximity thereto.

The present invention relates to a slow-release drug stent for nasal cavity, which comprises a main body and at least one bottom formed by interweaving silk threads or silk bundles with each other to form a grid structure, the main body extends circumferentially and has ends opposite to each other, and the bottom The curved surface protrudes outwards, the periphery of the bottom is aligned with the edge of the end, and the main body and the bottom are loaded with slow-release medicine for treating sinusitis. The invention also provides a method for forming the sustained-release drug stent used in the nasal cavity. The slow-release drug stent for nasal cavity provided by the present invention uses the wall of the main body to carry out adhering treatment on the wound surface, and at the same time uses the bottom to extend into the pit of the diseased part for adhering treatment, thereby acting on the inflammation in the pit and effectively reducing Mucosal inflammation and edema, promote mucosal healing, reduce scar formation, and eliminate postoperative adhesions.

The present invention relates to a composition comprising at least one poloxamer compound for use in the treatment of a fistula in an individual.

The invention provides application of Jian indigo naturalis in preparation of medicine for treating ulcerative colitis. The result shows that the clinical response, clinical remission and mucous membrane healing effects of the single Jian indigo naturalis after oral administration for 8 weeks are satisfactory, and the Jian indigo naturalis has a good curative effect on hormone-dependent or anti-TNF-alpha refractory UC. Clinical tests and animal experiments show that the Jian indigo naturalis has a good curative effect, is convenient for administration, the ulcerative colitis can be effectivelytreated; no severe adverse reactions, the Jian indigo naturalis can be orally taken to quickly relieve hematochezia; the clinical response rate, the clinical remission rate and the mucous membrane healing rate are higher than those of a placebo group; meanwhile, animal experiments also prove that the Jian indigo naturalis can effectively reduce the disease activity index of model animals, maintain animal weight, improve colon pathological injury, reduce the serum pro-inflammatory factor level, inhibit activation of related inflammatory signal channels and promote mucosal healing, and has goodclinical application prospects.

The present invention relates to a pharmaceutical composition for preventing or treating inflammatory bowel disease containing a tumor necrosis factor alpha inhibitor and prostaglandin E2 that induce regeneration or recovery of damaged intestinal mucosa. As the pharmaceutical composition for preventing or treating inflammatory bowel disease contains the tumor necrosis factor alpha inhibitor and prostaglandin E2 as active ingredients, it may be used to treat inflammatory bowel disease by improving reconstitution of damaged intestinal mucosa and the intestinal mucosal healing ability.

Mucosal healing is an indication to the disease activity level in patients affected by inflammatory bowel diseases, and it is thus far mainly monitored by endoscopy. Instead or in addition to endoscopy, the invention provides blood test using biomarkers and an index that allows a practitioner to assess the status of mucosal healing, to change or adapt dosage of treatment and to predict which patient will become responder versus non-responder to treatment as assessed by endoscopy. While none of neutrophils cell count, c-reactive protein (CRP), Human type of Cathelicidin (LL-37), or Chitinase 3-like 1 (CHI3L1) alone is able to provide an assessment means of mucosal healing, the invention provides a novel combination of the levels of these biomarkers to assess the level of mucosal healing in relation to endoscopic healing.

The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for treating Crohn's disease and application thereof. The invention discloses a traditional Chinese medicine composition for treating Crohn's disease. The traditional Chinese medicine composition is prepared from the following raw materials: 30 to 60 g of herba agrimoniae, 30 to 60 g of radix millettiae speciosae, 30 to 60 g of roasted radix puerariae, 15 to 30 g of rhizoma atractylodis macrocephalae, 15 to 30 g of poria cocos, 10 to 30 g of semen coicis, 5 to 15 g of fructus forsythiae, 5 to 15 g of herba artemisiae scopariae, 5 to 10 g of radix angelicae sinensis, 15 to 20 g of endothelium corneum gigeriae galli, 5 to 10 g of stiff silkworm, 10 to 20 g of fructus alpiniae oxyphyllae, 5 to 10 g of cortex moutan, 15 to 30 In the traditional Chinese medicine composition, hairyvein agrimony and beautiful millettia root serve as monarch drugs, bighead atractylodes rhizome, poria cocos, fructus alpiniae oxyphyllae and stewed radix puerariae serve as ministerial drugs, fructus forsythiae, moutan bark, stiff silkworm, thunberg fritillary bulb and angelica sinensis serve as adjuvant drugs, and oriental wormwood, endothelium corneum gigeriae galli and coix seeds serve as conductant drugs. Through the compatibility of monarch, minister, assistant and guide, the traditional Chinese medicine composition has the effect of inducing and relieving Crohn disease patients and has the tendency of promoting mucous membrane healing.

The present invention relates to ionic compositions for enhancing wound healing, particularly in the sinonasal cavity. The ionic components of the composition can include potassium, calcium, rubidium, zinc, bromide, and magnesium in an isotonic solution. In other embodiments, the ionic components of the composition can include magnesium, bromide, sulfate, sodium, and chloride. Methods of enhancing wound healing, enhancing sinonasal mucosal healing, promoting mucosal reciliation, and debriding tissue by administering the compositions of the present invention are also presented.